Last updated: 2026-09-08 09:12:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
BioRestorative Therapies, Inc. (BRTX) operates in the SERVICES-MISC HEALTH & ALLIED SERVICES, NEC sector and is listed on NASDAQ. The stock is currently priced at $0,15, with a market capitalization of $4,09M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0,14 to $34,60. This page covers its latest market performance, valuation, price trends and company information.
$4,09M | |
$0,15 | |
$178,00 | |
$0,14 | |
$0,14 | |
521,90K | |
23,29K | |
-- | |
$34,60 | |
$0,14 | |
-- | |
-- |
BioRestorative Therapies, Inc. (BRTX) is trading at $0,15 in pre-market trading as of 2026-09-04 23:50:00, up 3,69% ($0,01) from the previous close of $0,14
Pre-market trading shows how investors are pricing BRTX before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, BioRestorative Therapies, Inc. (BRTX) moved from $4,12 to $0,15, representing a decline of 96,46% ($3,97).
The stock traded between $0,14 and $4,50 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 41,30 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0,0%
BRTX is currently trading at $0,15, placing it 0,0% of the way from its 52-week low of $0,14 to its 52-week high of $34,60. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
| Industry | SERVICES-MISC HEALTH & ALLIED SERVICES, NEC |
| Employees | 14 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of BioRestorative Therapies, Inc. (BRTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.